Evidence map›Paper›PMID 42428109›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Cancer trends in England in younger adults from 2001-2023: comparing incidence, mortality and stage at diagnosis.

Amy Berrington de Gonzalez, Esme O'Brien, Zoey Richards, Reuben Frost, Meredith S Shiel, Aislinn Macklin-Doherty, Montserrat Garcia-Closas

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amy Berrington de GonzalezDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.
Esme O'BrienDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.
Zoey RichardsDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.
Reuben FrostDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.
Meredith S ShielDivision of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, MD, USA.
Aislinn Macklin-DohertyDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.
Montserrat Garcia-ClosasDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To compare trends in incidence and mortality rates for cancers with rising incidence in younger adults in England, and to assess whether increasing incidence is observed for early-stage, late-stage or both types of disease. Methods and analysis: We used cancer incidence and mortality data from English National Disease Registration Service (2001-2023). Analyses focused on 12 cancers with increasing incidence (on average) in younger adults (20-49 years) and more than 500 cases diagnosed in 2023. Trends were quantified by estimating the average annual percentage changes (AAPCs) and 95% confidence intervals (CI) using Joinpoint regression and by calculating the excess number of cancer cases in 2023 compared to 2001. Age-standardised rates (ASRs) of early (stage 1-2) and late-stage (stage 3-4) disease were compared between 2013 (the earliest year available) to 2023. Results: There were 31,385 cancers diagnosed in younger adults in 2023 compared to 244,384 in older adults. The most common cancers diagnosed in younger adults were female breast (n=8,504), colorectal (n=2,977) and melanoma (n=2,767). Of the 12 cancers that were increasing in younger adults between 2001 and 2023, only two also had increasing mortality rates: endometrial (AAPC[95%CI]= incidence 2.9%[2.4-3.4%] and mortality 4.0%[2.1-6.0%]) and colorectal cancer (AAPC[95%CI]= incidence 3.2%[2.8-3.6%] and mortality 1.9%[1.1-2.7%]). For thyroid cancer mortality rates were stable and for the other cancers (female breast, testicular, ovarian, kidney, brain, prostate, Hodgkin lymphoma and leukaemia) although incidence rates were increasing, mortality rates were decreasing, on average. Of the ten cancers with available stage data six showed increases in incidence rates for both early and late-stage disease between 2013 and 2023. Four cancers showed increases only in late-stage disease (female breast, ovarian, melanoma and Hodgkin lymphoma), while thyroid cancer showed an increase only in early-stage disease. Conclusions: These population-wide analyses of national data from England, combining cancer incidence, mortality and stage-stratified incidence trends, highlight several public health and research priorities. These include identifying the causes of increasing colorectal cancer incidence in younger adults, given the marked increases in mortality and late-stage disease, and of increasing breast cancer incidence, which affects the largest number of younger adults and is increasing only for late-stage disease.

Identifiers

PMID42428109
PMCPMC13345574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.